
|Articles|July 1, 2004
Genaera begins more squalamine trials
Genaera Corp. will begin three phase II trials on squalamine, its systemically administered anti-angiogenic drug.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
SubscribeAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Port Delivery System Therapies in Retinal Vascular Diseases
2
Offline smartphone AI accurately detects DR, glaucoma, and AMD in real-world study
3
Polyendocrine metabolic ovarian syndrome: looking past the reproductive system to the eye
4
Safety Considerations in Retinal Vascular Diseases
5






















